LYMPHOMAS

A 100% overall response rate was achieved with the combination of lenalidomide and obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma that was refractory to rituximab, according to findings of a single-arm, phase I/II trial presented at the 2019 American Society of Hematology Annual Meeting and Exposition.<br /> &nbsp;

Findings from a subgroup analysis of the phase III AUGMENT trial of patients aged 70 or older with indolent non-Hodgkin lymphoma showed a 34% reduction in the risk of disease progression or death compared with rituximab plus placebo, according data presented at the 2019 American Society of Hematology Annual Meeting and Exposition.<br /> &nbsp;

A high rate of rapid and durable complete responses were observed in patients with aggressive relapsed/refractory large B-cell lymphoma treated with lisocabtagene maraleucel.

Patients with&nbsp;refractory large B-cell lymphoma who were treated with Axi-cel had a&nbsp;3-year overall survival rate of 47%, according to an updated analysis of the&nbsp;phase II ZUMA-1 trial.&nbsp;

Complete remissions were achieved in greater than 20% of patients&nbsp;with highly refractory non-Hodgkin lymphomas who had been&nbsp;previously been treated with chimeric antigen receptor T-cell therapy with&nbsp;Mosunetuzumab, a novel bispecific antibody,&nbsp;according to study results presented at the 2019 American Society of Hematology Annual Meeting.

Hodgkin lymphoma represents approximately 10% of all cases of malignant lymphoma. This group of diseases most commonly affects adolescent and young adults, although approximately 20% to 25% of patients are aged &ge;60 years at diagnosis.

Andrew M. Evens, DO, MSc, discusses the significance of the results from the phase III ECHELON-1 trial in which patients with stage III/IV classical Hodgkin lymphoma were treated with the combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine.

In November 2019, the FDA approved a number of treatments, including acalabrutinib for the treatment of chronic lymphocytic leukemia and small lymphocytic leukemia, as well as zanubrutinib for the treatment of mantle cell lymphoma. A biosimilar for pegfilgrastim was also approved under indications.

Hodgkin lymphoma represents approximately 10% of all cases of malignant lymphoma. This group of diseases most commonly affects adolescent and young adults, although approximately 20% to 25% of patients are aged &ge;60 years at diagnosis. Advanced-stage disease is generally classified as Ann Arbor stage III to IV, but clinical trials often incorporate patients with high-risk stage II disease, such as those with B symptoms, multiple sites, or bulky disease

The phase III B-MIND study of the investigational humanized Fc-engineered monoclonal antibody, tafasitamab plus bendamustine versus rituximab plus bendamustine for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, has passed the pre-planned, event-driven interim analysis for futility, resulting in a recommendation to increase the number of study participants from 330 to 450, according to a press release from MorphoSys.

Basem William, MD, discusses challenges in treating patients with cutaneous and peripheral T-cell lymphomas, as well as the challenges in conducting clinical trials in this patient population.

Non-Hodgkin Lymphoma